{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:27:12Z","timestamp":1791322032908,"version":"4.3.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.healun.2013.06.008","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T09:55:42Z","timestamp":1376560542000},"page":"889-896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["One-year experience with intravenous treprostinil for pulmonary arterial hypertension"],"prefix":"10.1016","volume":"32","author":[{"given":"Raymond L.","family":"Benza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor F.","family":"Tapson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardi","family":"Gomberg-Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Poms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn J.","family":"Barst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2013.06.008_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2013.06.008_bib2","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2013.06.008_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2013.06.008_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2013.06.008_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2013.06.008_bib6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1016\/j.healun.2013.06.008_bib7","first-page":"1S41","article-title":"[A critical analysis of survival in idiopathic pulmonary arterial hypertension]","volume":"39","author":"Humbert","year":"2010","journal-title":"Presse Med"},{"key":"10.1016\/j.healun.2013.06.008_bib8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1378\/chest.11-0676","article-title":"The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension","volume":"141","author":"Benza","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.06.008_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1183\/09059180.00003109","article-title":"Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy","volume":"18","author":"Delcroix","year":"2009","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.healun.2013.06.008_bib10","doi-asserted-by":"crossref","first-page":"903A","DOI":"10.1378\/chest.1118152","article-title":"Use of parenteral prostanoids at time of death in patients with pulmonary arterial hypertension enrolled in REVEAL","volume":"140","author":"Farber","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.06.008_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin\u00ae) administered by the intravenous and subcutaneous route to normal volunteers","volume":"44","author":"Laliberte","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.healun.2013.06.008_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0091270007309708","article-title":"Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion","volume":"48","author":"McSwain","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.healun.2013.06.008_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.healun.2013.06.008_bib14","first-page":"425","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"A randomized, controlled trial. Ann Intern Med"},{"key":"10.1016\/j.healun.2013.06.008_bib15","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension. The impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2013.06.008_bib16","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2013.06.008_bib17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.healun.2013.06.008_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/112972980500600404","article-title":"Continuous low volume delivery of intravenous treprostinil via a central venous catheter with a miniature pump in a conscious dog model","volume":"6","author":"Laliberte","year":"2005","journal-title":"J Vasc Access"},{"key":"10.1016\/j.healun.2013.06.008_bib19","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/ajhp\/60.9.916","article-title":"Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents","volume":"60","author":"Phares","year":"2003","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.healun.2013.06.008_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0b013e31802b3184","article-title":"Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension","volume":"49","author":"Sitbon","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.healun.2013.06.008_bib21","doi-asserted-by":"crossref","unstructured":"McLaughlin VV, Archer SL, Badesch DB, et al. ACCF\/AHA 2009 expert consensus document on pulmonary hypertension. J Am Coll Cardiol 2009;53:1573\u2013619.","DOI":"10.1016\/j.jacc.2009.01.004"},{"key":"10.1016\/j.healun.2013.06.008_bib22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.06.008_bib23","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.healun.2013.06.008_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4037\/ccn2007.27.2.41","article-title":"Practical aspects of continuous intravenous treprostinil therapy","volume":"27","author":"Widlitz","year":"2007","journal-title":"Crit Care Nurse"},{"key":"10.1016\/j.healun.2013.06.008_bib25","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1378\/chest.129.6.1636","article-title":"Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension","volume":"129","author":"Lang","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.06.008_bib26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.healun.2012.02.025","article-title":"Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension","volume":"31","author":"Sadushi-Koli\u00e7i","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2013.06.008_bib27","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2013.06.008_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3949\/ccjm.74.11.789","article-title":"Treating pulmonary arterial hypertension: cautious hope in a deadly disease","volume":"74","author":"Minai","year":"2007","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.healun.2013.06.008_bib29","first-page":"170","article-title":"Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006","volume":"56","author":"Centers for Disease Control and Prevention (CDC)","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.healun.2013.06.008_bib30","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1086\/605320","article-title":"Closed-hub systems with protected connections and the reduction of risk of catheter-related bloodstream infection in pediatric patients receiving intravenous prostanoid therapy for pulmonary hypertension","volume":"30","author":"Ivy","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.healun.2013.06.008_bib31","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1378\/chest.11-0245","article-title":"The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension","volume":"141","author":"Rich","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.healun.2013.06.008_bib32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1742-1241.2009.02307.x","article-title":"Stability and antimicrobial effectiveness of treprostinil sodium in sterile diluent for Flolan","volume":"64","author":"Zaccardelli","year":"2010","journal-title":"Int J Clin Pract"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249813013004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249813013004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:26:24Z","timestamp":1760948784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249813013004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1053249813013004"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2013.06.008","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One-year experience with intravenous treprostinil for pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2013.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}